OPGN Stock Overview
A precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
OpGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.71 |
| 52 Week High | US$9.90 |
| 52 Week Low | US$0.66 |
| Beta | -0.62 |
| 1 Month Change | -52.67% |
| 3 Month Change | -62.63% |
| 1 Year Change | -83.49% |
| 3 Year Change | -99.68% |
| 5 Year Change | -99.70% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
OpGen to raise $3.38M in direct stock offering
Sep 30OpGen's subsidiary signs R&D agreement with FIND
Sep 20Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement
Aug 31OpGen launches sequencing services for infectious diseases in US
Aug 25OpGen GAAP EPS of -$0.13 beats by $0.02, revenue of $1M in-line
Aug 11OpGen reports preliminary revenue estimate for Q2 2022
Jul 08OpGen gains on insider buying
Jun 15OpGen submits 510(k) summary to FDA for Acuitas AMR Gene Panel for Isolates
Jun 07OpGen reports prelim Q4 & FY20 revenue
Jan 13OpGen subsidiary Curetis and Annar ink Unyvero distribution partnership for Colombia
Jan 05OpGen launches $10M private placement
Nov 24OpGen EPS misses by $0.04, beats on revenue
Nov 11OpGen's subsidiary and collaborators secures German funding to develop such a molecular diagnostics platform
Oct 28Shareholder Returns
| OPGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -33.6% | -3.8% | -2.7% |
| 1Y | -83.5% | -2.6% | 23.4% |
Return vs Industry: OPGN underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: OPGN underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| OPGN volatility | |
|---|---|
| OPGN Average Weekly Movement | 19.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: OPGN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OPGN's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 93 | John Tan | www.opgen.com |
OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company’s products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services.
OpGen, Inc. Fundamentals Summary
| OPGN fundamental statistics | |
|---|---|
| Market cap | US$7.29m |
| Earnings (TTM) | -US$9.92m |
| Revenue (TTM) | US$1.27m |
5.6x
P/S Ratio-0.7x
P/E RatioIs OPGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPGN income statement (TTM) | |
|---|---|
| Revenue | US$1.27m |
| Cost of Revenue | US$1.59m |
| Gross Profit | -US$323.88k |
| Other Expenses | US$9.59m |
| Earnings | -US$9.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | -25.59% |
| Net Profit Margin | -783.50% |
| Debt/Equity Ratio | 0% |
How did OPGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 23:19 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
OpGen, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Haynor | Alliance Global Partners |
| null null | Brookline Capital Markets |
| Nidhi Singh | Edison Investment Research |